



US007566539B2

(12) **United States Patent**
LaRosa

(10) **Patent No.:** **US 7,566,539 B2**
(45) **Date of Patent:** **Jul. 28, 2009**

(54) **ANTI-CCR2 ANTIBODIES AND METHODS OF USE THEREFOR**

(75) Inventor: **Gregory J LaRosa**, Newton, MA (US)

(73) Assignee: **Millennium Pharmaceuticals, Inc.**, Cambridge, MA (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 353 days.

(21) Appl. No.: **10/656,805**

(22) Filed: **Sep. 5, 2003**

(65) **Prior Publication Data**

US 2005/0048052 A1 Mar. 3, 2005

Related U.S. Application Data

(63) Continuation of application No. 09/898,513, filed on Jul. 3, 2001, now abandoned, which is a continuation of application No. 09/121,781, filed on Jul. 23, 1998, now Pat. No. 6,312,689.

(51) **Int. Cl.**

G01N 33/53 (2006.01)

G01N 33/567 (2006.01)

G01N 33/574 (2006.01)

C07K 17/00 (2006.01)

(52) **U.S. Cl.** **435/7.1; 435/7.2; 435/7.21; 435/7.23**

(58) **Field of Classification Search** None
See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

4,816,397 A 3/1989 Boss et al.
4,816,567 A 3/1989 Cabilly et al.
5,225,539 A 7/1993 Winter
5,440,021 A 8/1995 Chuntharapai et al.
5,543,503 A 8/1996 Chuntharapai et al.
5,571,713 A 11/1996 Lyle et al.
5,585,089 A 12/1996 Queen et al.
5,657,277 A 8/1997 Shirley
5,693,761 A 12/1997 Queen et al.
5,693,762 A 12/1997 Queen et al.
5,707,815 A 1/1998 Charo et al.
5,808,960 A 9/1998 McClure
5,858,089 A * 1/1999 Martinovic 118/13
5,859,205 A 1/1999 Adair et al.
5,985,279 A 11/1999 Waldmann et al.
6,006,339 A 12/1999 McClure
6,075,181 A * 6/2000 Kucherlapati et al. 800/25
6,084,075 A * 7/2000 Lind et al. 530/388.22
6,312,689 B1 11/2001 LaRosa
6,352,832 B1 3/2002 LaRosa et al.
6,395,497 B1 5/2002 LaRosa
6,406,694 B1 6/2002 LaRosa
6,406,865 B2 6/2002 LaRosa
6,448,021 B1 9/2002 LaRosa
6,451,522 B2 9/2002 LaRosa
6,458,353 B1 10/2002 LaRosa
6,491,915 B2 12/2002 LaRosa

6,696,550 B2 2/2004 LaRosa et al.
7,053,202 B2 5/2006 O'Keefe et al.
2003/0165494 A1 9/2003 LaRosa et al.
2004/0126851 A1 7/2004 LaRosa et al.
2004/0132980 A1 7/2004 LaRosa et al.
2004/0151721 A1 8/2004 O'Keefe et al.
2004/0265303 A1 12/2004 LaRosa et al.
2006/0147445 A1 7/2006 O'Keefe et al.

FOREIGN PATENT DOCUMENTS

WO WO 91/09967 7/1991
WO WO 94/09128 4/1994
WO WO 94/12214 6/1994
WO WO 95/08576 3/1995
WO WO 95/19436 7/1995
WO WO 97/31949 * 9/1997
WO WO 97/47319 12/1997
WO WO 98/42360 10/1998
WO WO 98/44953 10/1998
WO WO 99/15666 4/1999
WO WO 00/05265 2/2000

OTHER PUBLICATIONS

Lederman et al. *Molecular Immunology*, 1991, 28;11:1171-1181.*
Li et al. *PNAS*, 1980, 77;6:3211-3214.*
Frade et al. *The Journal of Immunology* 1997, 159:5576-5584.*
Li et al. *Biochemistry* 2000, 39;6:296-309.*
Förster, R., et al., "A general method for screening mAbs specific for G-protein coupled receptors as exemplified by using epitope tagged BLR1-transfected 293 cells and solid-phase cell ELISA", *Biochemical and Biophysical Research Communications*, 196(3):1496-1503 (1993).
Boring, L., et al., "Decreased lesion formation in CCR2^{-/-} mice reveals a role for chemokines in the initiation of atherosclerosis", *Nature*, 394(27):894-897 (1998).
Ylä-Herttuala, S., et al., "Expression of monocyte chemoattractant protein 1 in macrophage-rich areas of human and rabbit atherosclerotic lesions", *Proc. Natl. Acad. Sci., USA* 88:5252-5256 (1991).
Taubman, M.B., et al., "JE mRNA Accumulates Rapidly in Aortic Injury and in Platelet-Derived Growth Factor-Stimulated Vascular Smooth Muscle Cells," *Circulation Research* 70(2): 314-325 (1992).
Feng, A., et al., "Red Wine Inhibits Monocyte Chemoattractant Protein-1 Expression and Modestly Reduces Neointimal Hyperplasia After Balloon Injury in Cholesterol-Fed Rabbits," *Circulation* 100:2254-2259 (1999).

(Continued)

Primary Examiner—Maher M Haddad
Assistant Examiner—Chun Dahle
(74) *Attorney, Agent, or Firm*—Lando & Anastasi, LLP

(57) **ABSTRACT**

The present invention relates to an antibody or functional fragment thereof which binds to a mammalian (e.g., human) CC-chemokine receptor 2 (CCR2) or a portion of the receptor and blocks binding of a ligand to the receptor. The invention further relates to a method of inhibiting the interaction of a cell bearing mammalian CCR2 with a ligand thereof, and to use of the antibodies and fragments in therapeutic, prophylactic and diagnostic methods.